 Last month, the NIH announced that it had found evidence of research misconduct by Eliezer Masliah, M.D., the head of the neuroscience division at the National Institute on Aging. The NIH announcement coincided with the Sept. 26 publication of an investigation by Science, finding that 132 papers published by Masliah appear to contain manipulated images. 

In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia dives into this issue with Matthew Schrag, M.D., Ph.D., a neuroscientist who contributed to the dossier outlining Masliah’s misconduct.

To learn more about the topics in this episode:  

NIH neuroscience leader committed research misconduct, agency investigation finds

Last month, the NIH announced that it had found evidence of research misconduct by Eliezer Masliah, M.D., the head of the neuroscience division at the National Institute on Aging. The NIH announcement coincided with the Sept. 26 publication of an investigation by Science, finding that 132 papers published by Masliah appear to contain manipulated images. 
In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia dives into this issue with Matthew Schrag, M.D., Ph.D., a neuroscientist who contributed to the dossier outlining Masliah’s misconduct.
To learn more about the topics in this episode:  
<a href="https://www.fiercebiotech.com/research/head-national-institute-aging-neuroscience-division-eliezer-masliah-found-have-committed">NIH neuroscience leader committed research misconduct, agency investigation finds</a>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

Misconduct and the future of neurodegenerative disease research

Each year, we dive into the world of biotech closures and layoffs, tracking the industry’s pulse as companies navigate high risks and harsh realities. 

In this week's episode of "The Top Line," Fierce editors Gabrielle Masson and Andrea Park take a closer look at this year’s biotech graveyard, which tracks biotechs that have shuttered or are in the process of winding down.  

They also discuss how we identify these closures, the trends we’re seeing and what might be in store as the year wraps up.  

To learn more about the topics in this episode: 
The 2024 Biotech Graveyard
Fierce Biotech Layoff Tracker 2024

Each year, we dive into the world of biotech closures and layoffs, tracking the industry’s pulse as companies navigate high risks and harsh realities. 
In this week's episode of "The Top Line," Fierce editors Gabrielle Masson and Andrea Park take a closer look at this year’s biotech graveyard, which tracks biotechs that have shuttered or are in the process of winding down.     They also discuss how we identify these closures, the trends we’re seeing and what might be in store as the year wraps up.  
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/special-reports/2024-biotech-graveyard">The 2024 Biotech Graveyard</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/fierce-biotech-layoff-tracker-2024">Fierce Biotech Layoff Tracker 2024</a></li>
</ul>

Dig into this year’s Fierce Biotech Graveyard, layoff numbers 

As the 2024 U.S. presidential election nears, the choice between Democratic nominee Vice President Kamala Harris and Republican nominee former President Donald Trump will shape the future of drug pricing policy.  

While both candidates have pledged to reduce drug costs, their approaches are likely to differ significantly.  

In this week's episode of "The Top Line," Fierce Pharma's Zoey Becker chats with John Barkett, managing director of BRG’s healthcare transactions and strategy practice and former senior policy advisor for healthcare delivery system reform on the White House Domestic Policy Council, about what we can expect from each candidate's potential presidency and how the Inflation Reduction Act could play a pivotal role.  

To learn more about the topics in this episode: 
With election nearing, BMO analysts don't expect major pharma shake-ups from either candidate
Biden touts drug pricing achievements as he steps down from reelection campaign
2024 forecast: Biden admin efforts show there's no pricing relief on the horizon for pharma

As the 2024 U.S. presidential election nears, the choice between Democratic nominee Vice President Kamala Harris and Republican nominee former President Donald Trump will shape the future of drug pricing policy.  
While both candidates have pledged to reduce drug costs, their approaches are likely to differ significantly.  
In this week's episode of "The Top Line," Fierce Pharma's Zoey Becker chats with John Barkett, managing director of BRG’s healthcare transactions and strategy practice and former senior policy advisor for healthcare delivery system reform on the White House Domestic Policy Council, about what we can expect from each candidate's potential presidency and how the Inflation Reduction Act could play a pivotal role.  
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/pharma/us-voting-day-weeks-away-big-waves-pharma-front-are-unlikely-either-presidential-candidate">With election nearing, BMO analysts don't expect major pharma shake-ups from either candidate</a></li>
<li><a href="https://www.fiercepharma.com/pharma/president-biden-steps-down-reelection-campaign-his-historic-drug-pricing-moves-remain">Biden touts drug pricing achievements as he steps down from reelection campaign</a></li>
<li><a href="https://www.fiercepharma.com/pharma/2024-forecast-recent-biden-administration-moves-show-theres-no-pricing-relief-industry">2024 forecast: Biden admin efforts show there's no pricing relief on the horizon for pharma</a></li>
</ul>

Drug pricing and the 2024 presidential election

Discover how Turbine Simulated Cell Technologies is transforming drug development by addressing biases in training data. Guests Bence Szalai, MD, PhD, and Istvan Taisz, MD, PhD, share insights on the challenges of biased AI models in biology and introduce their groundbreaking framework, EFFECT (Evaluation Framework for Predicting Efficacy of Cancer Treatment).

Learn how Turbine's innovative bias detector ensures meaningful predictions, enhancing the accuracy of drug response models. Explore their tailored in silico biomarker discovery process, including a collaboration with Cancer Research Horizons to identify the right patient populations for new cancer drugs.

By integrating recent patient samples, Turbine achieves remarkable predictive capabilities, significantly improving model accuracy. This episode is essential for anyone interested in the future of biotechnology and precision medicine. Don’t miss this opportunity to understand how Turbine is shaping the landscape of drug development.

Listen now and be part of the conversation that’s paving the way for more effective cancer treatments.

Discover how Turbine Simulated Cell Technologies is transforming drug development by addressing biases in training data. Guests Bence Szalai, MD, PhD, and Istvan Taisz, MD, PhD, share insights on the challenges of biased AI models in biology and introduce their groundbreaking framework, EFFECT (Evaluation Framework for Predicting Efficacy of Cancer Treatment).
Learn how Turbine's innovative bias detector ensures meaningful predictions, enhancing the accuracy of drug response models. Explore their tailored in silico biomarker discovery process, including a collaboration with Cancer Research Horizons to identify the right patient populations for new cancer drugs.
By integrating recent patient samples, Turbine achieves remarkable predictive capabilities, significantly improving model accuracy. This episode is essential for anyone interested in the future of biotechnology and precision medicine. Don’t miss this opportunity to understand how Turbine is shaping the landscape of drug development.
Listen now and be part of the conversation that’s paving the way for more effective cancer treatments.

Explore how Turbine AI is revolutionizing drug development by tackling biases in data for more effective cancer treatments.

Misconduct and the future of neurodegenerative disease research

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips